Why the study?
Do direct oral anticoagulants provide a favorable benefit-risk ratio compared to vitamin K antagonists in elderly patients with non-valvular atrial fibrillation?
Do direct oral anticoagulants provide a favorable benefit-risk ratio compared to vitamin K antagonists in elderly patients with non-valvular atrial fibrillation?
The benefit-risk ratio of direct oral anticoagulants in elderly patients with non-valvular atrial fibrillation should be assessed individually for each molecule and patient profile.
Benefit-risk assessment of direct oral anticoagulants in elderly AF requires molecule- and profile-specific evaluation; leaves open need for targeted comparative trials.
Atrial fibrillation is the most frequent rhythm disorder in elderly patients. Moreover, the risk of stroke and the bleeding risk under anticoagulant treatment are the highest in this population. Vitamin K antagonists were until now the reference treatment of the anticoagulant treatment and they demonstrated a net benefit, including in elderly patients. The availability of the new oral anticoagulants, which do not require biological monitoring, simplified the anticoagulant treatment. However, data for the use of these molecules in elderly population remain limited. The benefit-risk ratio must not be assessed for this therapeutic class taken as a whole but for each molecule and according to the patient profile.
No takes yet. Share an insight, caveat, or question.
Tayaa et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: